Dr. Andrew Zelenetz spoke with Cancer Network about the importance of determining the cell of origin in patients with DLBCL.
Andrew Zelenetz, MD, PhD
Advertisement
Articles by Andrew Zelenetz, MD, PhD
The basis for the increased risks of cytomegalovirus and P. carinii infections with DENSE-R-CHOP-14 was puzzling, said Dr. Zelenetz of Memorial Sloan Kettering Cancer Center.
Advertisement
Latest Updated Articles
- Selective benefit in high-risk patients, but won’t alter clinical practice
Published: September 1st 2008 | Updated:
Determining the Cell of Origin in DLBCLPublished: September 26th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
2
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
3
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
4
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
5
